Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Friday an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku Co Ltd, granting rights for the development and commercialisation of Vicore's drug candidate C21 in Japan.
Vicore will receive an upfront payment of USD10m and stands to gain up to USD275m in milestone payments, along with tiered royalty payments.
Nippon Shinyaku will initially focus on developing C21 for idiopathic pulmonary fibrosis (IPF), aiming to address the limited treatment options for approximately 34,000 patients in Japan.
Vicore retains all rights to C21 outside of Japan.
C21, an oral therapy, has shown promising results in stabilising or improving lung function in IPF patients. A global Phase 2b ASPIRE study is planned to begin in the first half of this year.
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
BerGenBio partners with Tempus to advance lung cancer drug
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults